Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups

International Journal of Cardiology

Volumn 204, Issue , 2016, Pages 88-94

  Lip, Gregory Y H ^a,b   Mitchell, Stephen A ^c   Liu, Xianchen ^d   Liu, Larry Z ^d,e   Phatak, Hemant ^f   Kachroo, Sumesh ^f   Batson, Sarah ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c Decision Resources Group   (United Kingdom)

^d PFIZER INC   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f BMS   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Stroke prevention

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; VITAMIN K GROUP;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EMBOLISM; HUMAN; LOW DRUG DOSE; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CHEMICALLY INDUCED; COMPARATIVE STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE III AS TOPIC; DABIGATRAN; HEMORRHAGE; HUMANS; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIVAROXABAN; THIAZOLES; VITAMIN K;

EID: 84955244002     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.11.084     Document Type: Article

References (59)

1. A.J. Camm, G.Y. Lip, R. De Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, and et al. focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 2012 2012
2. S. Colilla, A. Crow, W. Petkun, D.E. Singer, T. Simon, and X. Liu Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population Am. J. Cardiol. 112 2013 1142 1147
3. M. Zoni-Berisso, F. Lercari, T. Carazza, and S. Domenicucci Epidemiology of atrial fibrillation: European perspective J. Clin. Epidemiol. 6 2014 213 220
4. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
5. R. Luengo-Fernandez, A.M. Gray, and P.M. Rothwell Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom Stroke 37 2006 2579 2587
6. B.M. Demaerschalk, H.M. Hwang, and G. Leung US cost burden of ischemic stroke: a systematic literature review Am. J. Manag. Care 16 2010 525 533
7. M.I. Aguilar, and R. Hart Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no history of stroke or transient ischemic attacks Stroke 39 4 2008 1399 1400
8. S. DeWilde, I.M. Carey, C. Emmas, N. Richards, and D.G. Cook Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care Heart 92 2006 1064 1070
9. T. Wilke, A. Groth, S. Mueller, M. Pfannkuche, F. Verheyen, R. Linder, and et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients Thromb. Haemost. 107 2012 1053 1065
10. S. Husted, R. de Caterina, F. Andreotti, H. Arnesen, F. Bachmann, K. Huber, and et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel Thromb. Haemost. 111 2014 781 782
11. Y. Kuroda, C. Hirayama, H. Hotoda, Y. Nishikawa, and A. Nishiwaki Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery Vasc. Health Risk Manag. 9 2013 593 598
12. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, and et al. Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
13. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
14. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891
15. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 369 2013 2093 2104
16. F. Dentali, N. Riva, M. Crowther, A.G. Turpie, G.Y. Lip, and W. Ageno Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 2012 2381 2391
17. C.S. Miller, S.M. Grandi, A. Shimony, K.B. Filion, and M.J. Eisenberg Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Am. J. Cardiol. 110 2012 453 460
18. D. Capodanno, P. Capranzano, G. Giacchi, V. Calvi, and C. Tamburino Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients Int. J. Cardiol. 2012
19. G.Y. Lip, T.B. Larsen, F. Skjoth, and L.H. Rasmussen Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation J. Am. Coll. Cardiol. 60 2012 738 746
20. L. Testa, M. Agnifili, R.A. Latini, R. Mattioli, S. Lanotte, F. De Marco, and et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 2012
21. A. Assiri, O. Al-Majzoub, A.O. Kanaan, J.L. Donovan, and M. Silva Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clin. Ther. 35 2013 967 984 (e2)
22. W.L. Baker, and O.J. Phung Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation Circ. Cardiovasc. Qual. Outcomes 5 2012 711 719
23. L.H. Rasmussen, T.B. Larsen, T. Graungaard, F. Skjoth, and G.Y. Lip Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 345 2012 e7097
24. S.A. Mitchell, T.A. Simon, S. Raza, D. Jakouloff, M.E. Orme, I. Lockhart, and et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis Clin. Appl. Thromb. Hemost. 19 2013 619 631
25. G. Biondi-Zoccai, V. Malavasi, F. D'Ascenzo, A. Abbate, P. Agostoni, M. Lotrionte, and et al. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses HSR Proc. Intensive Care Cardiovasc. Anesth. 5 2013 40 54
26. C. Cameron, D. Coyle, T. Richter, S. Kelly, K. Gauthier, S. Steiner, and et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation BMJ Open 4 2014 e004301
27. W. Fu, H. Guo, J. Guo, K. Lin, H. Wang, Y. Zhang, and et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis J. Cardiovasc. Med. (Hagerstown) 15 2014 873 879
28. A. Messori, V. Fadda, D. Maratea, S. Trippoli, and C. Marinai Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation Int. J. Clin. Pharmacol. Ther. 53 2015 211 219
29. P. Verdecchia, F. Angeli, C. Bartolini, V. De Filippo, A. Aita, L. Di Giacomo, and et al. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach Expert Opin. Drug Saf. 14 2015 7 20
30. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J. Clin. Epidemiol. 50 1997 683 691
31. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. H. JPT, and S. Green The Cochrane Collaboration 2011
32. S. Dias, N.J. Welton, A.J. Sutton, and A.E. Ades NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials. 2011 (last updated August 2011)
33. S.P. Brooks, and A. Gelman Alternative methods for monitoring convergence of iterative simulations J. Comput. Graph. Stat. 7 1998 434 455
34. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, and L. Wallentin Newly identified events in the RE-LY trial N. Engl. J. Med. 363 2010 1875 1876
35. G.A. Colditz, J.N. Miller, and F. Mosteller How study design affects outcomes in comparisons of therapy. I: Medical Stat Med. 8 1989 441 454
36. J. Oldgren, M. Alings, H. Darius, H.C. Diener, J. Eikelboom, M.D. Ezekowitz, and et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial Ann. Intern. Med. 155 2011 660 667 W204
37. J.D. Easton, R.D. Lopes, M.C. Bahit, D.M. Wojdyla, C.B. Granger, L. Wallentin, and et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial Lancet Neurol. 11 2012 503 511
38. H.C. Diener, S.J. Connolly, M.D. Ezekowitz, L. Wallentin, P.A. Reilly, S. Yang, and et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial Lancet Neurol. 9 2010 1157 1163
39. G.J. Hankey, M.R. Patel, S.R. Stevens, R.C. Becker, G. Breithardt, A. Carolei, and et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF Lancet Neurol. 11 2012 315 322
40. J.W. Gorter Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups Neurology 53 1999 1319 1327
41. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342 1993 1255 1262
42. K.W. Phillips, and J. Ansell Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management Expert. Rev. Cardiovasc. Ther. 6 2008 57 70
43. G. Palareti, C. Legnani, B. Cosmi, G. Guazzaloca, M. Cini, and S. Mattarozzi Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence J. Thromb. Haemost. 3 2005 955 961
44. Rivaroxaban (XARELTO) FDA Briefing Slideset for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). September 8th, 2011
45. C.J. Gonzalez-Quesada, and R.P. Giugliano Comparison of the Phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice Am. J. Cardiovasc. Drugs 14 2014 111 127
46. K.F. Schulz, I. Chalmers, R.J. Hayes, and D.G. Altman Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 273 1995 408 412
47. M. Cucherat Bias-Corrected Indirect Comparison Meta-Analysis of New Oral Anticoagulant in Atrial Fibrillation 2012 ISPOR Berlin
48. W.M. O'Neil, S.A. Welner, and G.Y. Lip Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions? Thromb. Haemost. 109 2013 497 503
49. S.H. Hohnloser Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma J. Am. Coll. Cardiol. 57 2011 181 183
50. S. Lahaye, S. Regpala, S. Lacombe, M. Sharma, S. Gibbens, D. Ball, and et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation Thromb. Haemost. 111 2014 465 473
51. D.A. Lane, and G.Y. Lip Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation Thromb. Haemost. 111 2014 381 383
52. J.W. Suh, R. Mehran, B.E. Claessen, K. Xu, U. Baber, G. Dangas, and et al. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial J. Am. Coll. Cardiol. 58 2011 1750 1756
53. E. Nikolsky, G.W. Stone, A.J. Kirtane, G.D. Dangas, A.J. Lansky, B. McLaurin, and et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial J. Am. Coll. Cardiol. 54 2009 1293 1302
54. R. De Caterina, S.J. Connolly, J. Pogue, S. Chrolavicius, A. Budaj, J. Morais, and et al. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W Eur. Heart J. 31 2010 2133 2140
55. P. Sardar, S. Chatterjee, W.C. Wu, E. Lichstein, J. Ghosh, S. Aikat, and et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons PLoS One 8 2013 e77694
56. S. Chatterjee, P. Sardar, G. Biondi-Zoccai, and D.J. Kumbhani New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation JAMA Neurol. 70 2013 1486 1490
57. S. Schneeweiss, J.J. Gagne, A.R. Patrick, N.K. Choudhry, and J. Avorn Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation Circ. Cardiovasc. Qual. Outcomes 5 2012 480 486
58. C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, M.D. Ezekowitz, and et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
59. S. Deitelzweig, A. Amin, Y. Jing, D. Makenbaeva, D. Wiederkehr, J. Lin, and et al. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥ 75 and < 75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials J. Med. Econ. 16 2013 1163 1168